Iovance Biotherapeutics Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Iovance Biotherapeutics de 61.7% y 43.7% respectivamente, mientras que el BPA crecerá en un 64.5% al año.

Información clave

61.7%

Tasa de crecimiento de los beneficios

64.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	43.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	21 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:0JDK - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	685	7	101	222	8
12/31/2025	413	-245	-154	-64	12
12/31/2024	161	-352	-267	-222	13
12/31/2023	1	-444	-384	-362	N/A
9/30/2023	1	-433	-377	-356	N/A
6/30/2023	0	-419	-355	-335	N/A
3/31/2023	N/A	-412	-333	-319	N/A
12/31/2022	N/A	-396	-313	-293	N/A
9/30/2022	N/A	-390	-294	-269	N/A
6/30/2022	N/A	-376	-296	-263	N/A
3/31/2022	N/A	-358	-278	-239	N/A
12/31/2021	N/A	-342	-266	-228	N/A
9/30/2021	N/A	-311	-290	-237	N/A
6/30/2021	N/A	-284	-281	-220	N/A
3/31/2021	N/A	-265	-259	-202	N/A
12/31/2020	N/A	-260	-252	-205	N/A
9/30/2020	N/A	-255	-223	-196	N/A
6/30/2020	N/A	-246	-208	-198	N/A
3/31/2020	N/A	-230	-202	-195	N/A
12/31/2019	N/A	-198	-166	-159	N/A
9/30/2019	N/A	-167	-140	-137	N/A
6/30/2019	N/A	-151	-125	-122	N/A
3/31/2019	N/A	-134	-114	-112	N/A
12/31/2018	N/A	-124	-102	-101	N/A
9/30/2018	N/A	-117	-92	-91	N/A
6/30/2018	N/A	-105	-85	-84	N/A
3/31/2018	N/A	-98	-78	-78	N/A
12/31/2017	N/A	-92	-80	-79	N/A
9/30/2017	N/A	-82	N/A	-70	N/A
6/30/2017	N/A	-128	N/A	-61	N/A
3/31/2017	N/A	-116	N/A	-47	N/A
12/31/2016	N/A	-102	N/A	-33	N/A
9/30/2016	N/A	-95	N/A	-27	N/A
6/30/2016	N/A	-34	N/A	-19	N/A
3/31/2016	N/A	-29	N/A	-19	N/A
12/31/2015	N/A	-28	N/A	-18	N/A
9/30/2015	N/A	-24	N/A	-15	N/A
6/30/2015	N/A	-19	N/A	-13	N/A
3/31/2015	N/A	-15	N/A	-10	N/A
12/31/2014	N/A	-12	N/A	-9	N/A
9/30/2014	N/A	-27	N/A	-8	N/A
6/30/2014	N/A	-34	N/A	-6	N/A
3/31/2014	N/A	-35	N/A	-6	N/A
12/31/2013	N/A	-34	N/A	-4	N/A
9/30/2013	N/A	-10	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 0JDK sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1.6%).

Beneficios vs. Mercado: Se prevé que 0JDK sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que 0JDK sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (43.7% al año) de 0JDK crezcan más rápidamente que los del mercado UK (3.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (43.7% al año) de 0JDK crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 0JDK se prevé que sea elevada dentro de 3 años.

Iovance Biotherapeutics Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Iovance Biotherapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Iovance Biotherapeutics, Inc. Agrees to A Proposed Settlement

Iovance Biotherapeutics, Inc. Agrees to A Proposed Settlement

Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer

New minor risk - Profitability

New major risk - Revenue and earnings growth

Iovance Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics, Inc.’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

New minor risk - Profitability

Iovance Biotherapeutics, Inc. Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

Iovance Biotherapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Financial position

Independent Director recently bought US$27m worth of stock

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Updates

New minor risk - Financial position

Iovance Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Shareholder dilution

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Accepts the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Insufficient new directors

Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited fo

Independent Director recently bought US$62k worth of stock

Independent Director recently bought US$65m worth of stock

Independent Director recently bought US$62k worth of stock

Iovance Biotherapeutics, Inc. Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (Sitc) Annual Meeting

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iovance Biotherapeutics, Inc. Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte Therapy

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Dynamic Index

Iovance Biotherapeutics, Inc. Appoints Wendy L. Dixon to Board of Directors

Independent Director recently bought US$51k worth of stock

Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

Iovance Biotherapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iovance Biotherapeutics, Inc. Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured At Iovance Cell Therapy Center (iCTC)

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer

Iovance Biotherapeutics, Inc. Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting

Iovance Biotherapeutics, Inc. Provides Regulatory Update for Lifileucel Potency Assays

Iovance Biotherapeutics, Inc. Appoints Igor Bilinsky as Chief Operating Officer

Iovance Biotherapeutics, Inc. Announces Board Changes

Iovance Biotherapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Iovance Biotherapeutics, Inc. Enters into a Lease Agreement with ARE-San Francisco No. 63, LLC

Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer

Iovance Biotherapeutics, Inc. Presents Clinical Data in Head and Neck Cancer At Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Iovance Biotherapeutics, Inc. Announces That Copy of an Abstract Submitted At Society for Immunotherapy in Cancer Annual Meeting Published by SITC

Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma

Iovance Biotherapeutics, Inc. Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma

Iovance Biotherapeutics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 2000 Index

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento